Navigation Links
Companion Diagnostics Market Report - Streamlining Drug Development and Advancing Personalized Medicine
Date:8/6/2013

DUBLIN, August 6, 2013 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/hkmzx8/companion) has announced the addition of the "Companion Diagnostics - Streamlining Drug Development and Advancing Personalized Medicine" report to their offering.

     (Logo: http://photos.prnewswire.com/prnh/20130307/600769)

Personalized healthcare encompasses tailored diagnostics, treatment and management of illnesses and diseases. Although the concept has been around for many years, it is only with the advent of companion diagnostics that personalized healthcare has started to gain ground. Companion diagnostics can be used in screening, monitoring, diagnosing and treating patients and can allow for stratification of patients to maximize efficacy and minimize risk.

Companion diagnostics can allow for a specific patient population to be identified which will ensure those patients who are most likely to respond are recruited for clinical trials and receive the therapy once the product is launched. Companion diagnostics can help to rationalize treatment decisions, with specifics such as accurate dosing, risks of adverse events and diagnostics being made possible through these tests. Through the use of companion diagnostics, the right treatment can be delivered to the right patient at the right time, delivering greater value and optimizing healthcare resource utilization.

Oncology has been the most active arena for companion diagnostics but, as research has advanced and new diagnostics developed, applications in other therapy areas are being discovered and established.

The report, Companion Diagnostics - Streamlining Drug Development and Advancing Personalized Medicine was written to support both the biopharmaceutical and diagnostic industries better understand the current challenges involved in developing products with a companion diagnostic, as well as the opportunities that will exist in the future. Recent success stories are identified and analyzed, and insights are provided throughout the study to support pharmaceutical & diagnostic strategic planning needs.

Key Reasons to Purchase

- This report provides an overview of advantages offered by companion diagnostics from early clinical development through to product launch and ongoing use in the patient population

- Understand what personalized medicine and companion diagnostics are and how these are expected to change the face of disease management

- Enables you to understand some of the key challenges faced during the development of companion diagnostics and recommendations on how to overcome them

- Provides an in-depth analysis of key case studies highlighting the successful application of companion diagnostics and how this has impacted company activities

- Gain insight into which pharmaceutical companies are leading the way in the development and application of companion diagnostics while assessing the key partnerships in place with diagnostics companies driving this sector forward

Key Topics Covered:

1. Executive summary

2. Methodology

3. Personalized medicine and companion diagnostics
- Personalized medicine overview
- What are biomarkers?
- What are companion diagnostics?

4. Advantages of companion diagnostics
- A more targeted patient population
- Focused drug development
- Rationalized treatment decisions
- Pharmacoeconomic advantages

5. Challenges in the development of companion diagnostics
- Logistical challenges
- Strategic business challenges
- Financial risks
- Regulatory challenges

6. Case studies
- Roche - leading the way with companion diagnostics
- Biogen Idec - a diagnostic to mitigate risk
- Xalkori - a sign of things to come?

7. A look to the future
- Companion diagnostics - a prerequisite to approval?
- A world beyond oncology
- Companies leading the way

For more information visit http://www.researchandmarkets.com/research/hkmzx8/companion.

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
U.S. Fax: +1-646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals


'/>"/>
SOURCE Research and Markets
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Companion Diagnostics Market, 2012-2023
2. Companion 2 Hospital Driver for Powering SynCardia Total Artificial Heart Wins Silver at Medical Design Excellence Awards
3. QIAGEN Expands Pipeline of Promising New Biomarkers for Development of Personalized Healthcare Companion Diagnostics
4. Algeta and Lumiphore Announce Further Expansion of Their Global Partnership for the Development of Targeted Alpha-pharmaceutical Cancer Therapeutics and Companion Diagnostics.
5. Epizyme to Partner to Develop DOT1L Companion Diagnostic
6. SynCardias Companion 2 Driver Named a Finalist in the Medical Design Excellence Awards
7. QIAGEN Enters Into Broad Collaboration Agreement With Lilly for the Development and Commercialization of Companion Diagnostics
8. Frost & Sullivan Recognizes ResearchDx for Its Impressive Performance in the Companion Diagnostics Sector
9. Perrigo Company To Acquire OTC Companion Animal Health Company, Velcera, Inc., For $160 Million
10. The Complete Guide to Companion Diagnostics: Market Environment Products and Companies
11. Merrimack Pharmaceuticals To Present Phase I Data On MM-302 And Preclinical Data On Companion Diagnostics Both For The Treatment Of HER2-Positive Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/7/2017)...  Diplomat Specialty Infusion Group, a brand of Diplomat Pharmacy, Inc. ... Iowa location. The Iowa ... an ISO 7 cleanroom—the standard needed to compound intravenous (IV) nutrition ... of pollutants. "Our new cleanroom ... serve our Iowa patients," said Phil ...
(Date:6/1/2017)... 2017 Nutriceutical Holdings (NH), parent company of ... and KD Pharma Group have decided to join forces ... Pharma Group. KD Pharma Group will become the largest ... the entire company. "We believe we have ... to growing the NH companies by providing us with ...
(Date:5/26/2017)... 2017  Endo International plc (NASDAQ: ENDP ) ... will represent the Company in a fireside chat at Goldman ... June 13, 2017 at 10:40 a.m. PT / 1:40 p.m. ... Rancho Palos Verdes, CA. ... be available on the Company,s website at http://www.endo.com/investors/overview . ...
Breaking Medicine Technology:
(Date:6/24/2017)... ... June 24, 2017 , ... Dr. ... 217 Portion Road in Lake Ronkonkoma, Dental365 offers patients high-quality and affordable routine ... visits to the dentist fit into their patients’ busy lifestyles. Dental365 also gladly ...
(Date:6/23/2017)... ... 2017 , ... "The Better Care Reconciliation Act (BCRA) falls ... people with all chronic conditions, including mental illnesses, while increasing the cost of ... Care Act (ACA) requirement that insurers cover pre-existing conditions, it does not require ...
(Date:6/23/2017)... ... 2017 , ... The Military Officers Association of America (MOAA) announced its support ... retired Marine Col. Thomas G. Bowman. , Bowman currently serves as the staff director ... with the issues and challenges veterans face with the VA. Following a 30-year career ...
(Date:6/23/2017)... ... June 23, 2017 , ... Goodcents Deli Fresh Subs today announced the opening ... 4210 SW 21st St. Topeka, Kan. 66604 (near 21st and Gage). It is owned ... owns three other locations in the Topeka and Bonner Springs, Kan. area. , ...
(Date:6/23/2017)... ... June 23, 2017 , ... 21 Middle East and South ... selected 21 leaders from government, business and civil society in 11 countries across the ... this fall, engaging in a transformative exchange of knowledge and ideas with the leading ...
Breaking Medicine News(10 mins):